LifeMD, Inc. (NASDAQ:LFMD) CEO Sells $129,750.00 in Stock

LifeMD, Inc. (NASDAQ:LFMD) CEO Justin Schreiber sold 25,000 shares of LifeMD stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $5.19, for a total value of $129,750.00. Following the sale, the chief executive officer now directly owns 2,703,715 shares of the company’s stock, valued at approximately $14,032,280.85. The trade was a 0.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Justin Schreiber also recently made the following trade(s):

• On Monday, December 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The shares were sold at an average price of $6.52, for a total value of $163,000.00.

LifeMD Price Performance

LifeMD stock opened at $5.54 on Wednesday. LifeMD, Inc. has a 52 week low of $3.99 and a 52 week high of $12.88. The firm has a market cap of $239.95 million, a P/E ratio of -8.66 and a beta of 1.49. The company has a debt-to-equity ratio of 10.83, a quick ratio of 0.78 and a current ratio of 0.83. The business’s fifty day moving average is $5.56 and its two-hundred day moving average is $5.56.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Mizuho initiated coverage on shares of LifeMD in a research report on Wednesday, December 4th. They set a “neutral” rating and a $7.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 target price on shares of LifeMD in a research note on Friday, September 20th. Lake Street Capital assumed coverage on LifeMD in a research report on Tuesday, December 10th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of LifeMD in a research report on Monday, November 11th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, LifeMD currently has an average rating of “Moderate Buy” and a consensus price target of $11.57.

Institutional Investors Weigh In On LifeMD

A number of hedge funds have recently added to or reduced their stakes in LFMD. Quest Partners LLC bought a new position in shares of LifeMD in the second quarter worth about $31,000. nVerses Capital LLC acquired a new stake in shares of LifeMD in the third quarter valued at approximately $46,000. Intech Investment Management LLC bought a new position in LifeMD in the 3rd quarter worth approximately $54,000. CWM LLC bought a new position in LifeMD in the 3rd quarter valued at $59,000. Finally, Los Angeles Capital Management LLC bought a new position in LifeMD in the 2nd quarter valued at $88,000. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.